ARCHIVES

Gilotrif Increases PFS Compared to Erlotinib In LUX-Lung 8 Phase III Head-to-Head Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 10 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: Senate Subcommittee Includes $2.7 Billion Increase for NIH in Budget Bill Markup

May 12, 2000

Joe Gray Moves To OHSU Knight Cancer Institute

January 21, 2011

Gallo Inquiry Complete; NCAB’s AIDS Committee Plans Q&A Session

June 12, 1992

Avastin improves lung cancer survival, opens options for new combinations. Details of Avastin risk vs. benefit to be released at ASCO annual meeting.

April 1, 2005

NRSAs Renamed For Kirschstein.

June 21, 2002

ASCO Annual Meeting: New Approaches For Treatment of Hematologic Malignancies

June 30, 2006